Core Viewpoint - Yisheng Biotechnology (01061) has seen a significant stock increase, rising nearly 9% in the afternoon session, with a current price of HKD 4.36 and a trading volume of HKD 5.2576 million [1] Group 1: Product Development and Exhibition - The company will participate in the 2026 Asia-Pacific Academy of Ophthalmology (APAO 2026) conference from February 5 to 8 at the Hong Kong Convention and Exhibition Centre [1] - Yisheng Biotechnology will showcase two core products: EB12-20145P (Bevacizumab) and a single-dose Beifu Shuh eye drop, both of which are demonstrating strong clinical development momentum [1] - The EB12-20145P project has been selected for poster presentation at the conference, where clinical progress and research insights will be shared with the international ophthalmology community [1] Group 2: Strategic Partnerships - The company announced an exclusive distribution agreement between its wholly-owned subsidiary Majeton and Osteopore, a global leader in 3D-printed bioresorbable implants [1] - This collaboration marks a milestone for the company in the oral market and expands its product line in dental, orthodontic, and maxillofacial solutions [1] - The partnership is expected to support the company's pursuit of sustainable growth in the Chinese market [1]

Core Viewpoint - Yisheng Biotechnology (01061) has seen a significant stock increase, rising nearly 9% in the afternoon session, with a current price of 4.36 HKD and a trading volume of 5.2576 million HKD [1] Group 1: Product Development and Events - The company will participate in the 2026 Asia-Pacific Academy of Ophthalmology (APAO 2026) conference from February 5 to 8 at the Hong Kong Convention and Exhibition Centre, showcasing its core products EB12-20145P (Bevacizumab) and single-dose Beifu Shuh eye drops [1] - EB12-20145P continues to demonstrate strong clinical development momentum and has been selected for poster presentation at the conference, where clinical progress and research insights will be shared with the international ophthalmology community [1] Group 2: Strategic Partnerships - The company announced an exclusive distribution agreement between its wholly-owned subsidiary Majeton and Osteopore, a global leader in 3D-printed bioresorbable implants [1] - This collaboration marks a milestone for the company in the oral market and expands its product line in dental, orthodontic, and maxillofacial solutions, supporting sustainable growth in the Chinese market [1]